Yet how will our system contemplate funding high-cost therapies that deliver potentially curative benefits over such a wide range of years - from 5 to 75 years.
New CAR-T data once again highlights the evaluation challenge
June 5, 2019 Latest NewsNews of the DayLatest Video
New Stories
-
Parliamentary inquiry recommends reforming access arrangements for lobbyists
May 8, 2024 - - Latest News -
Island announces reallocation of US grant funding to support dengue fever trial
May 8, 2024 - - Latest News -
New TGA approvals for UCB's interleukin inhibitor
May 8, 2024 - - Latest News -
Home Affairs Minister reveals the facts on the independence of advisory committees
May 8, 2024 - - BioPharma -
AusBiotech policy leader appointed to lead BioMelbourne Network
May 8, 2024 - - BioPharma -
Momentum Clinical Research recruiting for Australian-based clinical trials
May 7, 2024 - - Australian Biotech -
TGA seeks nominations for statutory advisory committees
May 7, 2024 - - Latest News